Pharmaceutical composition for treating and preventing respiratory tract pathogen infection and application

A pathogenic infection and respiratory technology, applied in the field of respiratory diseases, can solve problems such as the lack of vaccines on the market, achieve good application prospects, improve lung lesions, and increase survival rates

Pending Publication Date: 2022-07-29
GUIZHOU MEDICAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Human Respiratory Syncytial Virus (HRSV) is the most important pathogen that causes viral pneumonia in children, and is also one of the important pathogens for lower respiratory tract infections in the elderly. The severe pneumonia caused by this virus infection can kill hundreds of thousands of children or the elderly every year , so far no vaccine has been released

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating and preventing respiratory tract pathogen infection and application
  • Pharmaceutical composition for treating and preventing respiratory tract pathogen infection and application
  • Pharmaceutical composition for treating and preventing respiratory tract pathogen infection and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] This example provides an in vitro antiviral validation experiment of rotenone.

[0052] The HRSV low-virulence strain HRSV-A-GZ08-0 and high-virulence strain HRSV-A-GZ08-18 used were referred to Zhang K, LiC, Luo Y S, et al.Establishment of a lethal aged mouse model of humanrespiratory syncytial virus infection. Antiviral Research, 2019, 161:125-133.

[0053] In vitro antiviral experiment: We infected HEp-2 cells with HRSV low-virulence strain HRSV-A-GZ08-0 and high-virulence strain HRSV-A-GZ08-18 for 1 hour, and then changed the medium to contain 1 μM, 0.75 μM, 0.5 μM , 0.25μM and 0.125μM concentration of rotenone in cell culture medium (DMEM-F12 / GlutaMax-I, 10565, Gibco; 2% FBS; 1% P / S) continued to culture, followed by TCID at 48 hours and 72 hours after infection, respectively 50 Virus titers in cell pellets and cell supernatants were determined and compared with real-time quantitative PCR.

[0054] result reference figure 1 and figure 2 shown, visible 48 hours...

Embodiment 2

[0060] In this example, the in vivo antiviral verification experiment of rotenone was carried out.

[0061] After infecting BALB / c mice with HRSV high-virulence strain HRSV-A-GZ08-18 (the same source as in Example 1), we dissolved rotenone in physiological saline at different concentrations, at 1.5 mg / kg, 1.0 mg / kg and 0.5 mg / kg. Mice were injected subcutaneously with mg / kg rotenone for 3 days, and HRSV-A-GZ08-18 virus control group and 1.5 mg / kg, 1.0 mg / kg and 0.5 mg / kg rotenone subcutaneous injection control groups were set at the same time.

[0062] Figure 5 4, 5, and 6 days after HRSV infection, the results of the measurement of mouse pneumovirus titers in the mice in the saline-treated group after HRSV infection and in the mice in the 1.0 mg / kg rotenone-treated group after HRSV infection, the measurement method is TCID 50Law. The results showed that the viral load in the lungs of mice in the saline-treated group on the 4th and 5th day after HRSV infection was significa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for treating and preventing respiratory tract pathogen infection and application, and relates to the technical field of respiratory tract diseases. The inventor finds new application of rotenone. In-vitro and in-vivo experiments prove that the rotenone can reduce the virus titer of human laryngocarcinoma epithelial cells infected by human respiratory syncytial virus (HRSV), improve the survival rate of animals and promote the weight of the infected animals to be gradually increased from low level. Tests prove that the rotenone has a good effect of resisting respiratory pathogens (especially respiratory infection viruses), has a good application prospect when being used for treating and / or preventing respiratory pathogen infection, and can be developed into corresponding drugs for treating or preventing respiratory pathogen infection. And good news is brought to pneumonia patients such as viral pneumonia.

Description

technical field [0001] The present invention relates to the technical field of respiratory diseases, in particular, to a pharmaceutical composition and application for the treatment and prevention of respiratory pathogen infection. Background technique [0002] Rotenone is a natural compound derived from the roots and stems of roten, cantaloupe, agave, and mung bean plants. Since its discovery in the late 19th century, rotenone has been widely used as an insecticide to control insects, ticks and lice, and as a fish insecticide to manage fish in lakes and reservoirs. In 2000, Betarbet et al. reproduced most of the behavioral, biochemical and pathological features of Parkinson's disease in rotenone-treated rats. Since then, rotenone has received extensive attention as an environmental neurotoxin involved in the pathogenesis of Parkinson's disease. In addition, rotenone-treated rats have now been used to create a common experimental model for studying the underlying mechanism...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K36/48A61P11/00A61P31/16A61P31/14A61P31/04
CPCA61K31/352A61K36/48A61P11/00A61P31/16A61P31/14A61P31/04
Inventor 张科罗语思杨筱萌沈祥春张晗溪
Owner GUIZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap